Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
Metabolomic insights will support the leading science and technology company in advancement of its drug early development programs across therapeutic areas.
MUNICH, GERMANY / MORRISVILLE, N.C., USA – August 3, 2020 – Metabolon, Inc., the global leader in metabolomics, has entered into a multi-year collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany, operates its biopharmaceuticals business in the U.S. and Canada as EMD Serono.
As a partner for exploratory metabolomics Metabolon will support clinical & translational research projects across therapeutic areas. The agreement is effective August 3rd, 2020.
“We are very happy that Merck KGaA, a global biopharma specialty innovator, has selected Metabolon to help further the advancement of their important work in bringing innovative therapeutics to patients,” said Michael Rasche, President & General Manager of Metabolon’s International Business. “We believe our proprietary Precision MetabolomicsTM solution can provide Merck KGaA Darmstadt, Germany, with actionable insights that will inform decision-making and enable novel discoveries in their early phase drug development programs. The execution of this long-term agreement is another important recognition of Metabolon as a world-class metabolomics solution provider.”
Metabolomics reflects biochemical activity within cells – and therefore more accurately represents a system’s real-time interaction with a treatment than other more traditional technologies. This real-time, in vivo view provides drug developers with a comprehensive way to “fingerprint” the model system and help accelerate decision-making by clarifying the mechanism of action (MOA) and identifying pharmacodynamic, efficacy and response biomarkers.
Through this collaboration, Metabolon will perform global metabolomics and provide full biological interpretation and analysis of the results to illuminate biomarkers and biochemical pathways observed, with a goal of improving both the speed and yield of Merck KGaA’s, Darmstadt, Germany, drug development pipeline.